Abstract | This article reviews novel developments in the behavioral and pharmacologic treatment of obesity and explores the potential contribution of genomics research to weight control. A comprehensive program of lifestyle modification, comprised of diet, physical activity and behavior therapy, induces a mean loss of 7-10% of initial weight in individuals with obesity. Two trials demonstrated that weight loss of this magnitude, combined with increased physical activity, substantially reduced the risk of developing type 2 diabetes mellitus in individuals with impaired glucose tolerance. A third trial is now investigating whether lifestyle intervention will reduce cardiovascular morbidity and mortality in overweight individuals who already have diabetes mellitus. Pharmacotherapy is recommended, in some patients, as an adjunct to lifestyle modification. Two medications-orlistat and sibutramine-are currently approved in the US for long-term weight loss. Both are efficacious when combined with lifestyle modification, although health concerns have been raised about the use of sibutramine. Several novel combination therapies, which target multiple hypothalamic pathways that regulate appetite and body weight, are currently under investigation. Genomic studies provide further evidence for the role of these pathways in the regulation of body weight. Identification of new genes controlling satiety and energy expenditure may yield valuable clues for the development of novel pharmacologic treatments.
Introduction
Individuals with obesity are encouraged to lose approxi mately 10% of their initial weight through consumption of a calorierestricted diet and an increase in physical activity, according to expert committees of the WHO and the NIH. 1, 2 This lifestyle modification approach is con sidered the corner stone of treatment for individuals with overweight or obesity ( Table 1) . [1] [2] [3] If lifestyle modifica tion alone is ineffec tive, pharmacotherapy may be con sidered for individuals with a BMI ≥30 kg/m 2 or for those with a BMI ≥27 kg/m 2 when comorbidities, such as hyper tension or type 2 diabetes mellitus, are present. 1, 2 Bariatric surgery is reserved for individuals with a BMI ≥40 kg/m 2 (or for patients with a BMI ≥35 kg/m 2 and comorbidities) who do not lose sufficient weight with lifestyle modification and pharmacotherapy. 1, 2 This article reviews developments in lifestyle modifica tion and pharmacotherapy for obesity and concludes with an examination of genes that contribute to obesity, which may yield new targets for pharmacologic inter vention and ultimately gene therapy.
Lifestyle modification
The benefits of lifestyle modification for the treatment of obesity have become evident from results of the Dia betes Prevention Program (DPP) 4 and the Finnish Diabetes Prevention Study, 5 which showed a 58% reduced risk of developing type 2 diabetes mellitus with lifestyle intervention compared with placebo. These two studies led to the initiation of the Look AHEAD (Action for Health in Diabetes) study, 6 which is the first prospec tive, randomized trial to examine whether weight loss, combined with increased physical activity, will decrease cardiovascular morbidity and mortality, including fatal and nonfatal myocardial infarction and stroke. A total of 5,145 overweight individuals with type 2 diabetes melli tus were randomly assigned to an intensive lifestyle inter vention (ILI), modeled on the DPP, or a diabetes support and education (DSE) group. 7 After 1 year, participants in the ILI group lost 8.6% of their initial weight compared with 0.7% in patients in the DSE group (P <0.001). 6 After 4 years, patients in the ILI group maintained a weight loss of 4.7% compared with 1.0% in individuals in the DSE group (P <0.001). 8 Clinically significant improvements in fitness, levels of HbA 1c and HDL cholesterol, and systolic blood pressure were also maintained by patients in the ILI group compared with those in the DSE group. Longterm followup, which is scheduled to conclude in 2014, will reveal whether these improvements are sufficient to reduce cardiovascular morbidity and mortality in the ILI group.
options for lifestyle modification In academic medical centers, lifestyle modification is typically provided weekly, according to a structured treat ment protocol, for an initial period of 16-26 weeks. 9, 10 Instruction in nutrition, suitable physical activities and longterm weight management is provided to groups of 10-20 indivi duals in sessions of 60-90 min duration by registered dietitians, behavioral psychologists or other healthcare professionals. 9, 10 Group treatment is more economical to provide and induces a larger initial weight loss than individual care, even in participants who report a prefer ence for individual treatment. 11 This phe nomenon is potentially due to feelings of camaraderie and support provided by other group members, as well as competition between participants. Treatment may also be delivered via the internet and email. 12 These latter approaches have the potential to reach the millions of individuals who would benefit from lifestyle modifica tion. The most successful internetbased programs, however, typically induce a loss of only 4-5% of initial weight, about half of the amount achieved with meetings that occur face to face.
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Diet Consistent with uS dietary guidelines, 16 lifestyle modifica tion programs typically encourage participants to consume a lowfat diet and to increase their intake of fruits, vegetables and whole grains. 17, 18 Nevertheless, lifestyle interventions can be combined with a variety of dietary approaches on the basis of individual prefer ences. Whereas lowcarbohydrate, low glycemic index and Mediterranean diets have all been found to induce shortterm weight loss, [19] [20] [21] [22] [23] [24] [25] [26] the optimal macronutrient composition (that is, the ratio of fats to carbohydrates to proteins) of weightloss diets has not been established. Table 2 presents selected randomized controlled trials that have examined weight loss with diets of varying macronutrient compositions. Despite the contest that has prevailed among advocators of these and other diets over the past decade, a randomized controlled trial 27 showed that macro nutrient composition in a specific diet did not affect shortterm or longterm weight loss when the prescribed energy deficit was held constant, at 750 kcal per day. 27 This finding reaffirms that calorie intake-not macro nutrient composition-determines weight loss. The amount or type of macronutrient, how ever, may affect the control of comorbid condi tions, such as type 2 diabetes mel litus and cardio vascular complications. 19, 20, 28 Dansinger and colleagues 26 have suggested that the optimal diet to induce weight loss is the one to which an individual adheres best.
Physical activity
Physical activity is critical for improving cardiovascular disease risk factors in individuals with obesity, regard less of its effects on body weight. 29, 30 Several studies have shown that cardiorespiratory fitness attenuates the increased mortality risk associated with obesity. [31] [32] [33] Individuals with obesity should strive to engage in ≥150 min per week of moderate to vigorous activity, such as brisk walking. 30 resistance training is particularly benefi cial for the maintenance of adipose tissuefree mass during weight loss. 34, 35 Multiple short periods of activity per day have been shown to be as effective as a single long period of activity for the induction of weight loss. 36, 37 Similarly, increasing lifestyle activity, which includes all physical activity that is not scheduled exercise, is as effec tive as traditional, programmed exercise for improving weight and cardiovascular health. 38, 39 Methods to increase lifestyle activity include taking the stairs instead of the ele vator, walking to nearby places instead of driving and doing yard work. Pedometers provide an inexpensive and con venient method of tracking increases in both lifestyle and programmed physical activity. 40 Cognitive behavioral therapy Cognitive behavioral therapy for obesity incorporates skills of selfmonitoring, stimulus control and cogni tive restructuring. 9, 10 Selfmonitoring includes teaching patients to keep detailed records of the types and amounts of food and beverage consumed each day, which enables participants to calculate their calorie intake. In addition, this method helps participants become aware of any pat terns to their intake, such as snacking in the evening. 9 Stimulus control techniques help patients manage cues (or triggers) associated with eating, and include exercises such as limiting eating to one room in the house, eating reVieWs at regular times of day and refraining from eating while engaging in other activities, such as driving. 9 Cognitive restructuring is based on the theory that a person's thoughts control their behavior (and their response to events). Cognitivebehavioral treatment teaches partici pants how to identify and challenge problem thinking patterns. 9 For example, thoughts such as "I shouldn't have eaten that cookie, I've blown it, I'll never be able to do this, " typically lead patients to give up on their diets. Patients are taught to practice the development of more adaptive thoughts, such as "That wasn't the best choice for me but I'll get back on track right now and eat fewer calories at my next meal to compensate. "
Long-term weight management
Patients treated by group lifestyle modification for 20-26 weeks lose an average of 7-10% of initial weight, but, in the absence of continuing care, regain about onethird of the lost weight in the year following treatment. 9, 10 Multiple factors seem to contribute to weight regain. 10 First, upon leaving their highly supportive treatment groups, patients return to a toxic environment that explicitly encourages them to consume large quantities of foods-high in fat, sugar and calories. 41 Second, metabolic adaptations to weight loss also probably contribute to weight regain. 10 For example, after weight loss, energy expended during physi cal activity is reduced by ≥40% as a result of an increased work efficiency of skeletal muscle. 42 Participation in weightmaintenance sessions, fol lowing acute weight loss, is the most reliable method of facilitating longterm weight control (with lifestyle modification). 10, 43 Individuals who attended group maintenance sessions every 2 weeks during the first year after weight reduction maintained 13.0 kg of a 13.2 kg weight loss, whereas study participants assigned to a control group had regained 5.1 kg by the end of the year. 44 Furthermore, Wing et al. 45 showed that monthly patientprovider contact, whether in person or via the internet, similarly improved the maintenance of a previous loss of 19.3 kg. This study revealed the importance of patients weighing themselves daily during weight maintenance and responding quickly to small increases in weight. 17 High levels of physical activity (≥200 min duration or energy expenditure of 2,500 kcal per week) are also criti cal for successful weightloss maintenance. 35, 46, 47 A high volume of activity may be needed to compensate for the increased work efficiency of skeletal muscle following weight loss. 42 
Pharmacologic treatment of obesity
Weightloss medications are recommended as an adjunct to lifestyle modification in patients unable to lose suf ficient weight (that is, ~10% of their initial weight) with diet and exercise alone. 2, 3 At present, only two medica tions-orlistat and sibutramine-are approved by the FDA for longterm weight loss (Table 3) . Despite their distinctly different mechanisms of action and adverse effect profiles, both medications, when combined with lifestyle modification, induced losses of approxi mately 10% of initial weight in trials of 1year or 2years duration. 4851 These losses were associated with marked improvements in several metabolic outcomes and risk factors of cardiovascular disease. 52 orlistat Orlistat, a pancreatic lipase inhibitor, prevents the hydro lysis and absorption of approximately 30% of dietary fat contained in a meal. 52, 53 This drug is prescribed as 120 mg, taken three times per day with meals. A metaanalysis, 54 which included 16 studies of approximately 10,000 par ticipants who were treated with orlistat or placebo for at least 1 year, reported a mean placebosubtracted weight loss of 2.9 kg.
The drug's mechanism of action often results in several gastrointestinal adverse effects, including abdominal pain, bloating, flatulence, oily stools and diarrhea. Some of these adverse effects can be reduced or avoided by limit ing the fat intake per meal to 15 g. Thus, patients are negatively reinforced to consume a lowfat diet.
Several serious cases of adverse hepatic effects (for example, cholestatic hepatitis and subacute liver failure) have been reported over the past 10 years, prompting the FDA to issue an update on the safety of orlistat in September 2009. 55, 56 The FDA's review of orlistat revealed that jaundice, abdominal pain and weakness were the most frequent liverrelated adverse events, whereas severe liver injury was rare. 56 At the present time, the FDA has not advised against the continued prescrip tion of the medication. Moreover, orlistat can now be purchased overthecounter in a lowstrength dose (60 mg). Of note, no substantial serious adverse effects were reported after 4 years of treatment with orlistat in a diabetes prevention trial. 57 sibutramine Sibutramine, a selective serotonin and norepi nephrine reuptake inhibitor, acts centrally to reduce food intake. 52, 53 The medication is prescribed at a dose of 10 mg or 15 mg once daily (typically in the morning). In a metaanalysis 54 that included seven studies on 2,838 participants treated with sibutramine for at least 1 year, the mean placebosubtracted weight loss was 4.2 kg. The largest weight losses were obtained when the medication was combined with a comprehensive program of life style modification. 58, 59 Common adverse effects include increased blood pressure and pulse rate, constipation, dry mouth and insomnia. Thus, health professionals must monitor blood pressure and heart rate regularly to determine that they remain at acceptable levels in patients receiving sibutramine.
Concerns about the safety of sibutramine arose fol lowing preliminary analysis of the ongoing Sibutramine Cardiovascular Outcomes (SCOuT) trial, 60 which is assessing the safety of sibutramine in individuals with preexisting cardiovascular diseases or diabetes melli tus. A higher rate of cardiovascular disease events was observed in the sibutramine group compared to placebo (11.4% versus 10.0%), although the increased risk was limited to participants with a prior history of cardio vascular diseaserelated complications. These results reVieWs underscore that sibutramine is contraindicated in indivi duals with preexisting cardiovascular diseases (that is, coronary artery disease, stroke or transient ischemic attack), cardiac arrhythmias, congestive heart failure, peripheral arterial disease and uncontrolled hyper tension. 61 Sibutramine currently remains available in the uS but was withdrawn from the European market in January 2010. 62 Phentermine Phentermine, a sympathomimetic amine that pro motes catecholamine release, has been available in the uS since 1959. A metaanalysis, 63 which included six random ized trials, lasting 2-24 weeks, reported a mean placebo subtracted weight loss of 3.6 kg. A 36week study, however, published in 1968, revealed a mean placebosubtracted loss of 7.5 kg. 64 Common adverse effects included insomnia, anxiety and other central nervous system effects. Additional studies revealed treatmentrelated events that included tachycardia, ele vated blood pressure, palpitations and gastrointestinal effects. 65 Phentermine is only recommended for short term use; its administration for a period >12 weeks is considered offlabel in the uS, whereas it is no longer a licensed drug in Europe. 65 Phentermine has also been prescribed in combination with other medications, most notably fenfluramine. The latter drug, however, was removed from the market in 1997 because of its association with cardiac valvulo pathy. 66 Phentermine was not implicated in this dis order and remains the most widely prescribed weightloss medication in the uS today, principally because of its 67 . ‡ Data from Haddock et al. 63 . Abbreviation: HTr2C, 5-hydroxytryptamine receptor 2C.
reVieWs efficacy and low cost. Other medications that have been used offlabel to achieve modest weight loss include fluoxetine, topiramate, diethylpropion, buproprion and zonisamide (Table 3) . 65, 67 novel therapies in development Given the complexity of the neural pathways that regu late appetite and body weight, investigators are searching for combination therapies that target multiple pathways to enhance weight loss (Table 3) . Combination therapies typically comprise agents that have been found to induce weight loss in other conditions, but may be more toler able because they are administered in lower doses than typically prescribed as individual components. 68 Many of the new combination therapies are designed to target multiple receptor subtypes in the arcuate nucleus (ArC) of the hypothalamus, an area of the brain critical for the control of energy homeostasis (Figure 1 ). Information about the body's current nutrient status and energy stores is conveyed to this region of the brain by peripheral hormones, such as leptin, ghrelin and insulin. Leptin binds to two opposing populations of neurons in the ArC. [69] [70] [71] These neurons include the orexigenic, appetiteinducing neuropeptide Y (NPY) and agouti related protein (AgrP) neurons and the anorexigenic, appetitesupressing proopiomelanocortin (POMC) neurons. Both NPY/AgrP and POMC neurons project from the ArC to the paraventricular nucleus (PvN) of the hypothalamus (as well as other brain regions), which contains a dense neuronal population that expresses the melanocortin receptor 4 (MC4r). When leptin binds to its receptor on POMC neurons, it promotes the release of melanotropin α (also known as αmelanocyte stimulat ing hormone [αMSH] ) and cocaine and amphetamine regulated transcript protein (CArT), which both bind to MC4r. Leptin inhibits activation of NPY and AgrP neurons, thus, decreasing inhibitory input to POMC neurons while simultaneously reducing the release of orexigenic signals which act at downstream targets. These two phenomena (inhibition of NPY/AgrP neurons and disinhibition of POMC/CArT neurons) lead to a sub sequent increase in the release of CArT and other ano rectic neuropeptides in the PvN. Activation of MC4r in the PvN by αMSH relays a satiety signal, resulting in a reduction in food intake. AgrP is an inverse agonist at the MC4r, leading to increased food intake. In short, both leptin and insulin activate POMC neurons and inhibit NPY neurons.
Naltrexone and bupropion
The opioid receptor antagonist naltrexone has been com bined with bupropion, a dopamine and norepi nephrine reuptake inhibitor. Bupropion seems to increase firing of POMC neurons, whereas nal trexone blocks the βendorphinmediated auto inhibition of these neurons, thereby amplifying the effect of bupropion. 72, 73 In a 24week, randomized, controlled trial of 419 patients with obesity, Greenway et al. 72 found that all three doses of naltrexone (16 mg, 32 mg and 48 mg), combined with bupropion (400 mg per day), produced statistically signifi cant placebosubtracted weight losses of 4.6%, 4.7% and 3.5%, respectively. A subsequent 56week, randomized, controlled trial of 793 study participants with obesity compared a sustainedrelease naltrexonebupropion formulation (32 mg plus 360 mg, respec tively) versus placebo, combined with intensive lifestyle modification. 73 A perprotocol analysis revealed that the patients treated with medication lost 9.3% of their initial weight, compared with 5.1% in participants who received placebo (P <0.001); A sensi tivity analysis, however, revealed smaller losses of 7.8% and 4.9%, respectively (P <0.001). Common adverse effects included nausea, headache, insomnia and constipation. A new drug ap plication was submitted to the FDA in March 2010.
Bupropion and zonisamide
Bupropion has also been combined with the anti epileptic agent zonisamide. The latter medication was found incidentally to induce weight loss in epilepsy trials. reVieWs A subsequent randomized, controlled trial of indivi duals with obesity demonstrated superior weight loss with zonisamide compared with placebo, when both were combined with a hypocaloric diet. 75 Zonisamide's precise mechanism of action for inducing weight loss is unknown, but it is thought to enhance serotonergic and dopaminergic activity. 75 In a 24week phase IIb trial (designed to assess drug efficacy), the combination of bupropion and zonisamide induced an 8.6% weight loss, compared to 1.1% for placebo. 76 The most common adverse events were headache, nausea, in somnia, anxiety and dry mouth. Phase III studies are currently in progress.
Phentermine and topiramate A combination of phentermine and controlledrelease topiramate, another antiepileptic agent, has been found to induce weight loss (by unknown mechanisms). 76 In a 24week, randomized, controlled trial of 200 indivi duals with obesity, Gadde et al. 77 found that the combination of phentermine and topiramate induced a weight loss of 11.4 kg, compared with losses of 6.6 kg with topiramate alone, 5.3 kg with phentermine alone and 2.2 kg with placebo. In a phase III trial, 756 patients with obesity were assigned to placebo, phentermine and controlled release topiramate (7.5 mg phentermine plus 46 mg topiramate or 15 mg phentermine plus 92 mg topira mate) or single agent doses that comprised these com binations. 78 Medication was prescribed in combination with lifestyle modification. After 6 months, patients in the placebo group had lost 1.7% of their initial weight, compared with 8.5% and 9.2% in the combination groups that received the low and high combination doses, respectively. Typical adverse events included headache, pares thesias (skin ting ling or numbness), dizziness, dry mouth, upper respiratory infections, nasopharyngitis and constipation. 79 In earlier studies, 79, 80 monotherapy with high doses of topiramate was associated with adverse neuro psychiatric events that included changes in cog nition. A new drug application for the combination of phentermine and controlledrelease topiramate was filed with the FDA in December 2009. On 15 July 2010, an FDA advisory panel voted against its approval by a vote of 10 to six. The final decision on this drug will be made by the FDA by the end of October 2010.
Pramlintide and metreleptin
The combination of pramlintide, an analog of islet amyloid polypeptide used in the treatment of diabetes mellitus, and recombinant human leptin was found to reduce food intake and weight in leptinresistant, diet induced obese rats. 81, 82 In a proofofconcept study, 83 177 patients with obesity were treated with either 360 μg pramlintide or 5 mg metreleptin twice daily, or a com bination of the two, for 24 weeks. All participants were initially treated with a calorierestricted diet and pram lintide for the first 4 weeks. Weight losses at week 20 were 7.2 kg, 7.2 kg and 9.9 kg, respectively. A placebo group was not included in this study. Common adverse effects included pain at the injection sites and nausea. In February 2010, plans to undertake phase III studies of pramlintide and metreleptin were announced.
Lorcaserin
In contrast to the medications described above, lorca serin is a monotherapeutic agent that selectively targets the 5hydroxytryptamine receptor 2C (HTr2C), to modulate appetite. 68 unlike the nonselective HTr agonist fenfluramine, lorcaserin is not thought to stimu late the HTr2B receptor, an effect that was associated with cardiac valvular disease. 68 Lorcaserin was found to produce dose dependent weight loss in preclinical and clinical studies. [84] [85] [86] A 2year, randomized trial included 3,182 patients with obesity who were assigned to either lorcaserin (10 mg twice daily) or placebo, combined with lifestyle modification. 87 Mean placebosubtracted weight loss at 1 year was 3.6 kg in the lorcaserin group (P <0.001). Compared with patients who received placebo, study participants treated with medication regained less weight during the second year (P <0.001). Echocardiograms per formed at baseline and after 6, 12, 18 and 24 months did not reveal a drugrelated effect on the development of valvulopathy. A new drug application for lorcaserin was filed with the FDA in December 2009.
Novel targets for pharmacotherapy
The development of obesity is highly influenced by genetics, with heritability estimates ranging between 20% and 80%. [88] [89] [90] [91] [92] Most genes that contribute to this condition are still unknown, but rare monogenic defects that cause earlyonset, severe obesity have shed new light on speci fic genes or genomic regions integral to the regulation of body weight. 93 Further identification of the pathways affected by these genes may elucidate novel targets for pharmacologic therapy. Development of receptor ligands (antagonists or agonists), or inhibitors of intracellular signaling mechanisms associated with these pathways, are of great interest to pharmaceutical companies tar geting obesity. Ever more sophisticated gene therapy techniques are being developed, in which inert virus vectors that encode particular genes (for example, leptin or POMC) are able to restore deficiencies associ ated with depletion (or mutation) of that gene. 94, 95 A benefit of these techniques is the high degree of location specifi city, as function can be restored in very specific areas of the central nervous system. 96 genetics and the leptin-melanocortin system Defects in the hypothalamic leptin-melanocortin cir cuits have been implicated in many of the known mono genic forms of obesity. In humans, defects in leptin or the leptin receptor are wellcharacterized, but are exceed ingly rare. 97 Other rare autosomal recessive mutations that result in hyperphagia and severe earlyonset obesity have been described in the POMC and prohormone con vertase 1 (PHC1) genes. Collectively, these autosomal recessive mutations account for only 32 reported cases of obesity worldwide. 97 Mutations in the melanocortin system, however, are more common and may underlie more cases of adult reVieWs obesity. These mutations are inherited in an autosomal dominant fashion, with severe obesity resulting from the inheritance of only one affected allele. 97 Mutations in MC4R are estimated to account for obesity in 1.8% of adults 98 and up to 6.0% of cases of severe obesity in children. 99 The prevalence of defects in this pathway has spurred the search for MC4r agonists.
Subtle variants in the genes implicated in monogenic obesity may also contribute to more common forms of obesity, which typically result from inter actions among numerous genes and the environment. In a large number of genomewide association studies, which were performed in individuals with obesity and those with obesityrelated phenotypes, the MC4R gene has been the most strongly replicated candidate gene. 100 Other success fully replicated associations were found for genes that encode adipokines and adipokine recep tors (for example, leptin and its receptor, adiponectin, resistin, TNF and interleukin 6). 93 Genetic variants in some of these genes have been associated with distinct eating patterns, such as extreme snacking behavior or consumption of excessive portion size. 101 other genes implicated in obesity Genomewide association studies represent a powerful new technology that has led to the identification of new candidate genes in several disorders, including obesity. With this approach, the entire genome is screened to identify new, unanticipated genetic variants associ ated with disease. 100 At present, common variants in three genes have been associated with an increased risk of obesity: the fat mass and obesity associated (FTO), MC4R, and neuroendocrine convertase 1 (PCSK1) genes. In association with these genes, 17 obesity loci have been identified (Table 4) .
The FTO gene was the first locus identified to harbor common variants that predispose humans unequivocally to obesity and excess fat mass. 102 Multiple studies have found that FTO variants are associated with increased appetite. [103] [104] [105] [106] Although the site of action of the FTO protein on energy balance remains unclear, FTO is highly expressed in the brain. 102, 107 Evidence from rodent studies suggests that Fto may modulate levels of Stat3, a transcription factor critical for leptin receptor signal ing. 108 Another genomewide association study of 17,000 individuals found common variants in the MC4R to be positively associated with BMI. 109 Both FTO and MC4R were validated as genes controlling BMI in two sub sequent studies that utilized genomewide association in very large cohorts. 110, 111 The PCSK1 gene was identi fied in a genomewide association study that included 1,380 Europeans with severe obesity. 112 All three genes are highly expressed in the central nervous system, par ticularly in the hypothalamus. 113 Although each allele explains only a small proportion of the variance in adult BMI, individuals who carry a high number of risk alleles have a markedly increased BMI. 113 Identification of new genes that control energy intake and expenditure may yield valuable clues about novel therapeutic targets, for which pharmacologic agents can be designed to correct absent or mutated gene products. 114 Although gene therapy may be a potential treatment for obesity in the future, marked limitations in gene delivery systems, safety and the reliable control of gene expression currently precludes its use in humans. 114, 115 Conclusions Lifestyle modification to treat obesity is effective in inducing and maintaining losses of approximately 7-10% of initial weight, which can prevent or ameliorate obesityrelated health complications, including type 2 diabetes mellitus and hypertension. Lifestyle modification incorporates both cognitive and behavioral techniques, including selfmonitoring, stimulus control and cogni tive restructuring. Pharmacotherapy is recom mended, in reVieWs some patients, as an adjunct to lifestyle modification to improve the induction and maintenance of weight loss. Several new combination therapies are currently under development. Advances in genomic technology have lead to the identification of many candidate genes for obesity, which may yield valuable clues for novel pharmacologic targets. Advances in pharmacologic treatment of obesity must be accompanied by thorough cost-effectiveness analyses and determination of which individuals with obesity will benefit the most from treatment. For example, the induction and maintenance of a 7-10% weight loss may prove to have the greatest health benefits-and cost savings-in persons at risk of type 2 diabetes mellitus. Improvements in the quality of life of patients, as a result of the prevention of diabetes mellitus, must be included in the cost-benefit analysis. ultimately, studies are needed to determine the cost of providing lifestyle modification and pharmacotherapy for individuals with obesity compared with the costs of treating type 2 diabetes mellitus and its associated complications.
Review criteria
A literature search was performed using PubMed and MEDLINE for original articles published from 1970 onwards focusing on "lifestyle modification," "behavioral weight management," "cognitive behavioral therapy," "pharmacotherapy for obesity," and "sibutramine," "orlistat," "phentermine." The senior author (T. A. Wadden) drew on his knowledge of the literature for each of these sections. For the sections on the neural regulation of energy homeostasis and gene therapy we searched PubMed and MEDLINE for original articles on "neural regulation" and "obesity", "gene therapy" and "obesity," and "ob gene," "pomc gene" and "fto gene." Again, several papers were identified by drawing on authors' own knowledge of the literature (M. L. Vetter and L. F. Faulconbridge). All articles identified were English-language, full-text papers, performed only in adults (except animal studies). Previous reviews from peer-reviewed journals were used in synthesizing data. We also searched the reference lists of identified articles for further papers.
